Elanco Animal Health Incorporated
ELANHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeElanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The $11.25B market capitalization puts ELAN squarely in large-cap range for its industry. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark.
Market Cap
$11.25B
Beta
1.71
P/E (TTM)
—
P/E (Fwd)
17.51
EPS (TTM)
$-0.41
EPS (Fwd)
$1.29
ROE
-3.0%
ROA
1.6%
Cash
$530.0M
Total Debt
$4.23B
Free CF
$826.9M
52W Change
1.1%
Annual Financials
Cash vs Debt
Where ELAN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ELAN finished 0.55% below its 150-day moving average ($23.62) and 1.43% below its 200-day moving average ($23.83). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ELAN overbought or oversold?
At the October 20, 2026 close, ELAN's RSI(14) was 61.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, ELAN has $530.0M in cash with $4.23B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $826.9M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -3.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.6% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $4.41B (2022) to $4.71B (2025).
With a beta above 1.5, ELAN tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Elanco Animal Health Incorporated's trajectory.